Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer
Authors:
- 24 March 2005
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 63 (3) , 231-239
Abstract
BACKGROUND: In the prostate, conversion of testosterone to dihydrotestosterone (DHT), by the enzymes 5α‐reductase types 1 and 2 (5αR1, 5αR2) is required for normal growth and probably also for development of prostate cancer (PCa). Finasteride, a 5αR2 inhibitor, was shown to reduce the prevalence of PCa in the Prostate Cancer Prevention Trial. However, inhibition of both 5αR isoenzymes causes a greater decrease in serum DHT. The aim of this study was to assess differential expression of these enzymes at various stages of PCa development.METHODS: Immunostaining for 5αR1 and 5αR2, using specific, well‐validated antibodies, was evaluated in 26 benign prostatic hyperplasia (BPH) (16 for 5αR2), 53 primary PCa (21 for 5αR2), 18 prostatic intraepithelial neoplasia (PIN), 12 primary PCa treated with neoadjuvant androgen ablation, 15 locally recurrent PCa specimens, and 18 PCa metastases.RESULTS: The mean area of moderate plus high intensity staining for 5αR1 increased from 4.8 ± 2.8% of total epithelial area in BPH, to 18.9 ± 5.7% in PIN, 17.0 ± 3.2% in primary cancer, 38.0 ± 7.3% in recurrent cancer, and 55.8 ± 8.5% in PCa metastases. The mean staining area for 5αR2 decreased from 58.8 ± 7.2% in BPH, to 21.1 ± 5.5% in PIN and 34.8 ± 6.7% in primary PCa. Staining for 5αR2 was increased in recurrent cancer and PCa metastases compared to primary PCa, at 58.7 ± 5.2% and 69.2 ± 8.7%, respectively.CONCLUSIONS: 5αR1 immunostaining is increased and 5αR2 immunostaining is decreased during development of PCa. In addition, there is increased expression of both 5αR isozymes in recurrent and metastatic cancers, suggesting that both isozymes may be important in the development and progression of PCa.Keywords
This publication has 24 references indexed in Scilit:
- EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCERJournal of Urology, 2004
- 5α-Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared With Benign Prostatic Hyperplasia EpitheliumJournal of Urology, 2003
- Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinomaThe Prostate, 2003
- Heterogeneity of 5 α-Reductase Gene Expression in Benign Prostatic HyperplasiaJournal of Urology, 2003
- Messenger Ribonucleic Acid Levels of Steroid 5 -Reductase 2 in Human Prostate Predict the Enzyme ActivityThe Journal of Clinical Endocrinology & Metabolism, 2001
- Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissueThe Journal of Steroid Biochemistry and Molecular Biology, 1999
- SELECTIVITY OF FINASTERIDE AS AN IN VIVO INHIBITOR OF 5 alpha-REDUCTASE ISOZYME ENZYMATIC ACTIVITY IN THE HUMAN PROSTATEJournal of Urology, 1999
- Kinetic analysis of steroid 5α-reductase activity at neutral pH in benign prostatic hyperplastic tissue: Evidence for type I isozyme activity in the human prostateThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 1992
- The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implicationsThe Prostate, 1986